Skip to main content

Table 2 Results from univariate survival analyses of aspirin intake and confounders on overall (OS), disease-free (DFS), and hematogenous metastasis-free (HMFS) survival

From: Effect of platelet inhibition with perioperative aspirin on survival in patients undergoing curative resection for pancreatic cancer: a propensity score matched analysis

Parameter Median (meana) OS (95% CI) in months 3-YSR 5-YSR Log-rank p Median (meana) DFS (95% CI) in months Log-rank p Median (meana) HMFS (95% CI) in months Log-rank p
Pt. on aspirin     *0.006   *0.001   *0.005
 Yes 46.5a (35.6–57.4) 61.1% 61.1%   26.0 (16.7–35.3)   41.9a (30.3–53.4)  
 No 24.6a (20.2–28.9) 26.3% n/a   10.5 (6.5–14.5)   16.3 (11.4–21.1)  
Age     0.405   0.348   0.957
 ≤ Median 26.5 (16.3–36.8) 40.9% 26.2%   14.5 (8.2–20.8)   17.9 (12.1–23.8)  
 > Median 24.9 (14.8–34.9) 27.4% n/a   13.5 (11.2–15.8)   21.5 (11.4–31.5)  
Sex     0.555   0.856   0.949
 Female 24.2 (16.2–32.2) 29.2% n/a   13.9 (11.7–16.1)   18.3 (7.3–29.4)  
 Male 27.1 (17.3–37.0) 36.7% 21.4%   13.5 (8.5–18.5)   19.7 (14.4–24.9)  
BMI     0.127   0.601   0.956
 ≤ Median 35.0 (19.4–50.6) 47.9% 28.9%   13.5 (6.7–20.3)   19.6 (13.6–25.7)  
 > Median 21.0 (17.3–24.6) 40.3% 24.3%   13.9 (10.5–17.3)   17.7 (7.3–28.1)  
ASA score     0.702   0.754   0.596
 ASA II 26.5 (17.7–35.4) 26.7% n/a   14.5 (10.9–18.1)   14.5 (10.9–18.1)  
 ASA III/IV 22.3 (14.4–30.2) 36.2% 21.2%   13.3 (9.7–16.9)   20.9 (12.7–29.0)  
Platelet count     0.598   0.720   0.616
 Normal 24.2 (17.6–30.8) 34.0% n/a   13.6 (11.0–16.2)   17.9 (11.4–24.4)  
 < 150 G/l 21.0 (9.8–32.2) n/a n/a   9.0 (7.8–10.2)   23.9a (14.8–32.9)  
 > 400 G/l 37.8 (0–81.7) 66,7% n/a   19.7 (0.8–38.6)   19.7 (0.8–38.5)  
Serum CA19-9     0.092   0.128   0.196
 ≤ Median 29.1 (19.3–38.8) 41.8% n/a   15.5 (12.3–18.7)   26.0 (15.0–37.0)  
 > Median 18.9 (11.3–26.5) 26.5% 21.2%   12.0 (7.0–17.0)   18.3 (10.7–25.9)  
Type of resection     0.314   0.995   0.999
 PD 21.0 (17.7–24.2) 29.4% 21.5%   12.8 (9.3–16.3)   18.3 (9.2–27.4)  
 DP 37.1 (21.6–52.6) 52.1% n/a   16.2 (14.7–17.7)   20.9 (14.4–27.3)  
 TP 26.5 (22.4–30.7) 30.0% n/a   14.5 (7.3–21.7)   16.8 (12.1–21.4)  
Tumor diameter     0.150   0.059   *0.032
 ≤ Median 27.0 (17.4–36.6) 41.7% 37.1%   13.9 (8.8–19.0)   27.0 (17.6–36.4)  
 > Median 22.0 (13.4–30.6) 28.2% n/a   12.8 (7.0–18.6)   16.2 (12.9–19.4)  
T-stage     0.352   0.249   0.402
 T1/2 37.8 (13.6–62.0) 60.0% 30.0%   16.7 (12.5–20.9)   19.7 (12.8–26.5)  
 T3 24.2 (17.4–31.0) 32.8% n/a   13.3 (10.3–16.3)   17.9 (11.4–24.5)  
Nodal stage     0.491   0.909   0.601
 N0 18.9 (13.9–23.9) 25.2% 25.2%   12.5 (9.1–15.9)   16.2 (8.1–24.2)  
 N1 26.5 (21.2–31.8) 39.5% n/a   13.6 (10.4–16.8)   18.3 (11.8–24.8)  
ELN     0.120   0.103   0.540
 ≤ Median 21.8 (15.7–27.9) 28.6% n/a   12.8 (9.0–16.6)   19.7 (14.3–25.0)  
 > Median 27.1 (15.6–38.6) 40.6% 34.8%   14.9 (9.3–20.5)   17.7 (2.8–32.6)  
Grading     0.840   0.713   0.240
 G1/2 35.0 (9.3–60.8) 41.0% n/a   16.2 (12.1–20.3)   27.2 (12.4–41.9)  
 G3 24.2 (18.3–30.1) 32.9% 24.0%   12.5 (9.0–16.0)   17.7 (11.6–23.8)  
Lymphovasc. invas     *0.039   0.095   *0.049
 L0 27.4 (18.8–36.0) 42.1% 31.2%   16.3 (13.8–18.8)   26.0 (18.0–34.0)  
 L1 18.9 (10.1–27.7) 24.6% n/a   9.0 (7.2–10.8)   13.9 (8.6–19.2)  
Vascular invasion     *0.039   **< 0.001   **< 0.001
 V0 27.0 (18.2–35.8) 38.7% 25.7%   16.3 (12.4–20.2)   24.9 (17.3–32.4)  
 V1 14.4 (12.1–16.6) 16.3% n/a   7.9 (6.4–9.4)   9.0 (4.5–13.6)  
Perineural invasion     0.424   0.153   0.216
 Pn0 35.0 (11.1–58.9) 40.4% 20.2%   27.8 (11.9–43.7)   32.7 (17.4–48.0)  
 Pn1 24.2 (17.2–31.2) 33.6% n/a   13.3 (10.3–16.3)   17.7 (12.2–23.2)  
R-status     0.366   0.756   0.225
 R0 wide 26.5 (18.3–34.8) 35.5% 24.3%   14.9 (11.2–18.6)   21.5 (11.4–31.5)  
 R0 narrow 29.1 (15.8–42.3) 39.6% n/a   13.9 (9.6–18.2)   17.9 (9.6–26.3)  
 R1 18.9 (6.0–31.8) 26.7% n/a   12.0 (4.6–19.4)   12.5 (1.2–23.7)  
Add. venous resect     0.248   0.494   0.994
 Yes 17.6 (6.0–29.1) 25.0% n/a   12.5 (6.3–18.7)   18.3 (9.3–27.4)  
 No 27.1 (19.0–35.2) 38.7% 22.7%   13.9 (11.6–16.2)   19.7 (12.7–26.6)  
Adjuvant therapy     0.010   0.634   0.672
 Yes 27.1 (14.2–40.1) 43.1% n/a   15.5 (12.2–18.8)   19.7 (12.3–27.0)  
 No unknown 12.4 (8.6–16.2)
19.3 (12.4–26.2)
n/a
26.9%
n/a
13.4%
  8.3 (7.5–9.1)
12.8 (8.3–17.3)
  21.5 (4.9–38.1)  
  1. BMI body mass index, ASA American Society of Anesthesiologists Score, PD pancreaticoduodenectomy, DP distal pancreatectomy, total pancreatectomy; ELN examined lymph nodes
  2. aMedian could not be calculated due to too many censored cases, mean survival is presented; patients with missing data were excluded in univariate analyses for the respective parameter
  3. *p < 0.05, **p ≤ 0.001